Trials / Unknown
UnknownNCT02520453
Adjuvant Durvalumab for Esophageal Cancer
Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2021-06-01
- Completion
- 2021-12-01
- First posted
- 2015-08-11
- Last updated
- 2019-12-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02520453. Inclusion in this directory is not an endorsement.